![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BRD1 |
Gene summary for BRD1 |
![]() |
Gene information | Species | Human | Gene symbol | BRD1 | Gene ID | 23774 |
Gene name | bromodomain containing 1 | |
Gene Alias | BRL | |
Cytomap | 22q13.33 | |
Gene Type | protein-coding | GO ID | GO:0002262 | UniProtAcc | A0A024R4V5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23774 | BRD1 | male-WTA | Human | Thyroid | PTC | 2.99e-21 | 1.33e-01 | 0.1037 |
23774 | BRD1 | PTC01 | Human | Thyroid | PTC | 4.45e-02 | -9.52e-03 | 0.1899 |
23774 | BRD1 | PTC04 | Human | Thyroid | PTC | 3.18e-11 | 2.53e-01 | 0.1927 |
23774 | BRD1 | PTC05 | Human | Thyroid | PTC | 2.19e-17 | 4.10e-01 | 0.2065 |
23774 | BRD1 | PTC06 | Human | Thyroid | PTC | 6.35e-30 | 5.92e-01 | 0.2057 |
23774 | BRD1 | PTC07 | Human | Thyroid | PTC | 1.64e-34 | 5.20e-01 | 0.2044 |
23774 | BRD1 | ATC12 | Human | Thyroid | ATC | 4.76e-07 | 7.78e-02 | 0.34 |
23774 | BRD1 | ATC13 | Human | Thyroid | ATC | 6.09e-32 | 5.61e-01 | 0.34 |
23774 | BRD1 | ATC2 | Human | Thyroid | ATC | 9.16e-11 | 7.10e-01 | 0.34 |
23774 | BRD1 | ATC3 | Human | Thyroid | ATC | 2.31e-02 | 1.49e-01 | 0.338 |
23774 | BRD1 | ATC4 | Human | Thyroid | ATC | 2.41e-08 | 1.25e-01 | 0.34 |
23774 | BRD1 | ATC5 | Human | Thyroid | ATC | 4.92e-34 | 6.17e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0030218210 | Thyroid | ATC | erythrocyte differentiation | 64/6293 | 120/18723 | 6.52e-06 | 6.76e-05 | 64 |
GO:0010038210 | Thyroid | ATC | response to metal ion | 165/6293 | 373/18723 | 1.07e-05 | 1.05e-04 | 165 |
GO:000736915 | Thyroid | ATC | gastrulation | 90/6293 | 185/18723 | 1.54e-05 | 1.43e-04 | 90 |
GO:004311224 | Thyroid | ATC | receptor metabolic process | 82/6293 | 166/18723 | 1.78e-05 | 1.63e-04 | 82 |
GO:007258315 | Thyroid | ATC | clathrin-dependent endocytosis | 30/6293 | 47/18723 | 2.16e-05 | 1.92e-04 | 30 |
GO:007266523 | Thyroid | ATC | protein localization to vacuole | 38/6293 | 67/18723 | 8.48e-05 | 6.33e-04 | 38 |
GO:004396611 | Thyroid | ATC | histone H3 acetylation | 34/6293 | 61/18723 | 3.10e-04 | 1.94e-03 | 34 |
GO:005507632 | Thyroid | ATC | transition metal ion homeostasis | 66/6293 | 138/18723 | 3.64e-04 | 2.25e-03 | 66 |
GO:004564625 | Thyroid | ATC | regulation of erythrocyte differentiation | 27/6293 | 47/18723 | 6.69e-04 | 3.77e-03 | 27 |
GO:005507214 | Thyroid | ATC | iron ion homeostasis | 41/6293 | 85/18723 | 3.62e-03 | 1.58e-02 | 41 |
GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
GO:003162310 | Thyroid | ATC | receptor internalization | 52/6293 | 113/18723 | 4.05e-03 | 1.74e-02 | 52 |
GO:0045637113 | Thyroid | ATC | regulation of myeloid cell differentiation | 89/6293 | 210/18723 | 4.75e-03 | 1.96e-02 | 89 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRD1 | SNV | Missense_Mutation | c.808G>A | p.Asp270Asn | p.D270N | O95696 | protein_coding | deleterious(0.03) | benign(0.062) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BRD1 | SNV | Missense_Mutation | c.1426N>A | p.Ala476Thr | p.A476T | O95696 | protein_coding | deleterious(0.01) | benign(0.234) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
BRD1 | SNV | Missense_Mutation | c.928N>A | p.Glu310Lys | p.E310K | O95696 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A28Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
BRD1 | deletion | Frame_Shift_Del | novel | c.1587delG | p.His530ThrfsTer9 | p.H530Tfs*9 | O95696 | protein_coding | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
BRD1 | SNV | Missense_Mutation | rs773212689 | c.3526N>T | p.Arg1176Cys | p.R1176C | O95696 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BRD1 | SNV | Missense_Mutation | c.643N>A | p.Ala215Thr | p.A215T | O95696 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
BRD1 | SNV | Missense_Mutation | novel | c.28N>T | p.Gly10Cys | p.G10C | O95696 | protein_coding | tolerated(0.08) | possibly_damaging(0.497) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BRD1 | SNV | Missense_Mutation | c.2020N>A | p.Gly674Ser | p.G674S | O95696 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-C5-A1MI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
BRD1 | SNV | Missense_Mutation | c.964N>T | p.Arg322Trp | p.R322W | O95696 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
BRD1 | SNV | Missense_Mutation | c.646N>A | p.Val216Met | p.V216M | O95696 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23774 | BRD1 | ENZYME | inhibitor | 252166774 | ||
23774 | BRD1 | ENZYME | inhibitor | 336446910 |
Page: 1 |